A phase 2 study of IBI110 (anti-LAG-3 antibody) plus sintilimab in patients with advanced alveolar soft part sarcoma
Latest Information Update: 09 Jul 2024
At a glance
- Drugs IBI 110 (Primary) ; Sintilimab
- Indications Alveolar soft part sarcoma
- Focus Therapeutic Use
Most Recent Events
- 09 Jul 2024 New trial record
- 04 Jun 2024 Results (As of January 20, 2024; n=28) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.